Spragens Jeffrey G
Known title: DirectorCIK: 0001410620
Spragens Jeffrey G's purchase track record
Spragens Jeffrey G has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/1/2021 | SABS | $131K | -22.4% | -65.6% | +4.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SABS | ▲ Buy | Grant | 82,987 | $100K | 12/7/2022 | View on chart |
| SABS | ▼ Sell | Other | 299,002 | $0 | 5/20/2022 | View on chart |
| SABS | ▲ Buy | Open Market | 13,000 | $131K | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting
SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.
SAB Biotherapeutics to Present SAB-142 Data at European Diabetes Meeting. SAB Biotherapeutics will share results for its SAB‑142 program at the 62nd Annual Meeting of the European Association for the Study of Diabetes. The presentation offers a chance to update investors on the clinical progress of this diabetes therapy. The company’s stock is currently trading near its 15‑touch support level of $3.70 and shows a volume spike, indicating growing interest.